Additional file 5: of ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth

Figure S4. Irf6 is upregulated in breast tumor cells after neoadjuvant trastuzumab-based therapy. Formalin-fixed, paraffin-embedded tumor sections obtained from patient 4 before (a, c) and after (b, d) the therapy were stained with an anti-Irf6 antibody. The samples were stained with hematoxylin (blue) and eosin (red) (H&E) (a, b) or with an anti-Irf6 antibody (brown) (d, e) and counterstained with hematoxylin (blue). (PPT 1479 kb)